



26 July 2023

Kanabo Group PLC
("Kanabo" or the "Company")

Admission and Total Voting Rights

The Company announces today, 26 July 2023, 18,749,999 number of ordinary shares were admitted to trading on the Standard List of the London Stock Exchange ("Admission")

Following Admission, for the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, Kanabo announces that the Company has 630,427,870 ordinary shares of 2.5p each in issue ("Ordinary Shares"), each share carrying the right to one vote. The figure of 630,427,870 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please visit <http://www.kanabogroup.com/> or contact the following:

Enquiries:

Kanabo Group plc

Avihu Tamir, Chief Executive Officer
Assaf Vardimon, Chief Financial Officer
Ian Mattioli, Non-Executive Chair of the Board

via Vigo Consulting
+44 (0)20 7390 0230

Peterhouse Capital Ltd (Financial Adviser and Broker)

Eran Zucker/ Lucy Williams / Charles Goodfellow

+44 (0)20 7469 0930

Vigo Consulting (Financial Public Relations/Investor Relations)

Jeremy Garcia / Fiona Hetherington / Verity Snow
kanabo@vigoconsulting.com

+44 (0)20 7390 0230

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.

The Company's partially owned subsidiary, Kanabo Agritech Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com for more information.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEEAAXKASEDEFA